| PainChek Ltd (PCK) ORDINARY FULLY PAID |
Health Care |
$80 |
Preliminary Final Report
|
29 Aug 2025 8:26AM |
$0.041 |
$0.039 |
fallen by
4.88%
|
|
PCK - Price-sensitive ASX Announcement
Full Release
Key Points
- PainChek Limited is focused on expanding its market presence, particularly with the PainChek App designed for pain assessment in non-verbal patients.
- The financial year ending 30 June 2025 marked significant growth and strategic investments aimed at global expansion.
- Key strategic focuses include the US market entry, continued growth in the Adult App, and penetration into the direct-to-parent market with the Infant App.
- Revenue from ordinary activities increased by 26% compared to the previous financial year.
- The group incurred a loss of $7.67 million, a decrease from the previous year's loss.
- The company completed a $7.5 million placement of ordinary shares, with settlement in August 2025.
- The US FDA De Novo clearance for the Adult App is a primary target, with the completion of necessary clinical validation studies.
- Significant partnerships have been established in the US to facilitate market entry and growth, particularly in the aged care sector.
- The group has continued its investment in research and development, with substantial grants received.
- PainChek has not paid or declared any dividends for the period, with a focus on reinvesting for growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PainChek Ltd (PCK) ORDINARY FULLY PAID |
Health Care |
$80 |
Preliminary Final Report
|
29 Aug 2025 8:26AM |
$0.041 |
$0.039 |
fallen by
4.88%
|
|
PCK - Price-sensitive ASX Announcement
Full Release
Key Points
- Reported a loss of AUD 7,672,226 for the year ended 30 June 2025.
- Revenue increased to AUD 3,362,427.
- Significant expenses in research and development, marketing, and corporate administration.
- Strategic initiatives focused on US market entry, growth of Adult App, and launch of Infant App.
- Secured AUD 7.5 million through share placement post-reporting period.
- No dividends were declared.
- Continued investment in research and development and operational expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$2,790 |
Annual Financial Results Presentation
|
29 Aug 2025 8:26AM |
$2.420 |
$2.180 |
fallen by
9.92%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenues from cell therapy products increased by 191%.
- Cash on hand at June 30, 2025, was US$162 million.
- FDA approval received for Ryoncil® for pediatric SR-aGvHD.
- Increased expenses due to commercial team expansion and product launch.
- Late-stage clinical trials initiated for various cell therapy indications.
- Efforts to expand Ryoncil®'s label for adult SR-aGvHD.
- Pivotal study planned for inflammatory colitis.
- Advancing multiple products towards FDA approval in the next year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$2,790 |
Annual Financial Results Presentation
|
29 Aug 2025 8:26AM |
$2.420 |
$2.180 |
fallen by
9.92%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- 191% increase in total revenues from cell therapy products.
- FDA approved Ryoncil® for pediatric SR-aGvHD.
- Plans to expand Ryoncil®'s label for adults with SR-aGvHD.
- Advancing phase 3 trials for chronic low back pain, heart failure, and inflammatory bowel diseases.
- Preparing for FDA approvals within six to twelve months.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NICO Resources Limited (NC1) ORDINARY FULLY PAID |
Materials |
$12 |
Change of Director's Interest Notice
|
29 Aug 2025 8:26AM |
$0.096 |
$0.098 |
risen by
2.08%
|
|
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$55 |
Annual Report to shareholders
|
29 Aug 2025 8:25AM |
$0.215 |
$0.220 |
risen by
2.33%
|
|
| Scalare Partners Holdings Limited (SCP) ORDINARY FULLY PAID |
Consumer Staple |
$5 |
FY25 Full Year Results Presentation and Update
|
29 Aug 2025 8:25AM |
$0.105 |
$0.105 |
fallen by
0%
|
|
SCP - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue increased by 26% year-on-year.
- Product and service revenue up 78% year-on-year to $2.9 million.
- Scalare focuses on early-stage tech investments in sectors like fintech and medtech.
- Portfolio value increased to $11.2 million as of 30 June 2025.
- Net loss before income tax reported at $3,090,619.
- Scalare's strategic acquisitions include the intended acquisition of Tank Stream Labs.
- 194% unrealised return on invested cash since inception.
- Total assets increased to $17,161,830.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Scalare Partners Holdings Limited (SCP) ORDINARY FULLY PAID |
Consumer Staple |
$5 |
FY25 Full Year Results Presentation and Update
|
29 Aug 2025 8:25AM |
$0.105 |
$0.105 |
fallen by
0%
|
|
SCP - Price-sensitive ASX Announcement
Full Release
Key Points
- Acquired Inhouse Ventures and Tank Stream Labs.
- Services revenue increased by 78% to $2.9 million.
- Supporting over 850 founders across various programs.
- Strategic focus on early-stage tech startups.
- Significant investments in Regtech, Fintech, and Medtech.
- Gross profit of $1.74 million and a net loss of $2.64 million.
- Ongoing growth through strategic acquisitions and partnerships.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Xamble Group Limited (XGL) CHESS DEPOSITARY INTERESTS 1:1 |
Communication Services |
$9 |
Appendix 4D Half-Year Report FY2025
|
29 Aug 2025 8:25AM |
$0.024 |
$0.028 |
risen by
16.67%
|
|
XGL - Price-sensitive ASX Announcement
Full Release
Key Points
- Net tangible asset per share decreased to 0.44 cents from 1.09 cents.
- No dividends were paid or declared during the period.
- Total comprehensive loss of A$1,524,465 was reported.
- Absence of revenue from Taiwan operations post-exit in Q4 FY2024.
- Principal activities include software development and online advertising.
- Financial statements were reviewed by auditors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Xamble Group Limited (XGL) CHESS DEPOSITARY INTERESTS 1:1 |
Communication Services |
$9 |
Appendix 4D Half-Year Report FY2025
|
29 Aug 2025 8:25AM |
$0.024 |
$0.028 |
risen by
16.67%
|
|
XGL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased by 39% to A$3.15 million in H1 FY2025.
- Loss attributable to owners increased by 112% to A$1.46 million.
- No dividends were declared or paid in the current period.
- Strategic exit from Taiwan operations in Q4 FY2024.
- Increased technology investments partly funded by MDAG.
- App downloads increased by 159%, and influencer community grew by 95%.
- CDI entitlement offer announced to raise up to A$1.35 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Scalare Partners Holdings Limited (SCP) ORDINARY FULLY PAID |
Consumer Staple |
$5 |
FY25 Appendix 4E and Annual Report
|
29 Aug 2025 8:25AM |
$0.105 |
$0.105 |
fallen by
0%
|
|
SCP - Price-sensitive ASX Announcement
Full Release
Key Points
- Scalare Partners Holdings Limited underwent a reverse acquisition by Scalare Partners Pty Ltd.
- Financial statements consolidate Scalare Partners Pty Ltd and Scalare Partners Holdings Limited as of June 2025.
- Issued capital increased significantly from $7,889,530 in 2024 to $13,544,378 in 2025.
- The company reported a loss of $2,645,490 for FY25.
- Revenue grew from $2.81 million in 2024 to $3.54 million in 2025.
- The report details the acquisition of Tech Ready Women Pty Ltd and InHouse Ventures Pty Ltd.
- The consolidation led to an increased share issuance and capital management activities.
- Financial assets at fair value increased from 2024 to 2025.
- Equity holders are informed about share-related details and substantial shareholders as of July 2025.
- Listed on the Australian Securities Exchange under ticker code SCP.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Scalare Partners Holdings Limited (SCP) ORDINARY FULLY PAID |
Consumer Staple |
$5 |
FY25 Appendix 4E and Annual Report
|
29 Aug 2025 8:25AM |
$0.105 |
$0.105 |
fallen by
0%
|
|
SCP - Price-sensitive ASX Announcement
Full Release
Key Points
- Scalare Partners Holdings Limited had a reverse acquisition by Scalare Partners Pty Ltd.
- For the financial year ending June 30, 2025, Scalare Partners Holdings reported a total net asset of AUD 13,434,042.
- The company's operating segment now includes operations in the USA as of February 2025.
- Scalare Partners Holdings Limited is listed on the Australian Securities Exchange under ticker SCP.
- The company issued 5,867,756 new shares and incurred a cost of AUD 212,908 in the process.
- A net loss of AUD 2,645,490 was recorded for the year ending June 30, 2025.
- Major financial assets include options, shares, and convertible notes totaling AUD 11,232,975.
- Scalare Partners Holdings Limited's equity increased due to the issue of shares and share-based payments.
- Key management personnel received a total remuneration of AUD 2,275,941 for 2025.
- The Annual General Meeting is scheduled for November 27, 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,351 |
FY25 Results Announcement
|
29 Aug 2025 8:24AM |
$3.940 |
$3.980 |
risen by
1.02%
|
|
BAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory NPAT increased by 117.0% to $28.1M.
- Pro-forma revenue decreased by 1.5% to $1,943.5M.
- Significant items post-tax amounted to $52.3M, mostly non-cash.
- Positive free cash flow generation improved by $31.0M over FY24.
- Cash conversion improved to 81.8% from 76.9% in FY24.
- Refinanced $170M of debt, with available liquidity over $340M.
- Final dividend of 5.5cps, total FY25 dividend of 13.5cps.
- Strategic focus on simplifying operations and reducing costs.
- Closure and relocation of 70 sites caused operational disruption.
- Investments in IT infrastructure and systems.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,351 |
FY25 Results Announcement
|
29 Aug 2025 8:24AM |
$3.940 |
$3.980 |
risen by
1.02%
|
|
BAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory NPAT of $28.1M, up 117.0% from FY24.
- Pro-forma group revenue of $1,943.5M, down 1.5% from FY24.
- Pro-forma EBITDA of $246.7M, down 4.1% from FY24.
- Trade segment revenue up 1.3% and EBITDA up 5.4%.
- Specialist Wholesale revenue down 3.2% while EBITDA improved by 5.2%.
- Continued challenging conditions in Retail and New Zealand segments.
- Strategic re-set focusing on simplifying operations and cost reduction.
- Investments in IT infrastructure and achieving $27.5M in cost savings.
- Positive free cash flow and a strong balance sheet.
- Final dividend of 5.5cps, total FY25 dividend of 13.5cps.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$80 |
AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL
|
29 Aug 2025 8:24AM |
$0.170 |
$0.165 |
fallen by
2.94%
|
|
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$133 |
Appendix 4G
|
29 Aug 2025 8:24AM |
$1.355 |
$1.435 |
risen by
5.90%
|
|
| Naos Emerging Opportunities Company Limited (NCC) ORDINARY FULLY PAID |
Financials |
$28 |
Change of Director's Interest Notice - S Evans
|
29 Aug 2025 8:24AM |
$0.370 |
$0.375 |
risen by
1.35%
|
|
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$133 |
NOL Corporate Governance Statement
|
29 Aug 2025 8:24AM |
$1.355 |
$1.435 |
risen by
5.90%
|
|
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$2,790 |
Preliminary Final Report including Appendix 4E
|
29 Aug 2025 8:23AM |
$2.420 |
$2.180 |
fallen by
9.92%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- Preliminary Final Report for the financial year ending June 30, 2024.
- Includes Appendix 4E detailing financial performance.
- Covers revenue, expenses, and net loss figures.
- Discusses strategic initiatives and clinical program progress.
- Focus on development and regulatory progress of remestemcel-L.
- Details on share-based payments and equity changes.
- Overview of financial position and cash flow.
- Impact of external factors on operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,351 |
FY25 Appendix 4E and Financial Report
|
29 Aug 2025 8:23AM |
$3.940 |
$3.980 |
risen by
1.02%
|
|
BAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit after income tax of $28,225,000.
- Total revenue of $1,975,767,000.
- Significant recovery from a prior year loss of $165,717,000.
- Major revenue contribution from Bapcor Trade segment.
- Key financial impacts include asset write-offs and restructuring.
- Total assets at $1,827,122,000 and total equity at $855,853,000.
- Focus on employee equity plans and share-based payments.
- Efforts on efficient capital allocation to enhance shareholder value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,351 |
FY25 Appendix 4E and Financial Report
|
29 Aug 2025 8:23AM |
$3.940 |
$3.980 |
risen by
1.02%
|
|
BAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Consolidation of warehouses and change in inventory costing policy
- Retrospective financial adjustments for prior periods
- Segment performance with total consolidated revenue of $1,975,767,000
- Detailed long-term incentive plans for executives
- Performance metrics include Return on Invested Capital and Total Shareholder Return
- FY25 ended with total equity of $855,853,000
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$133 |
NobleOak FY25 Results Presentation
|
29 Aug 2025 8:23AM |
$1.355 |
$1.435 |
risen by
5.90%
|
|
NOL - Price-sensitive ASX Announcement
Full Release
Key Points
- NobleOak Life Limited reported a strong financial performance for FY25, with a 20% increase in in-force premiums, reaching $464.2 million.
- The company achieved a statutory net profit after tax (NPAT) of $7.1 million, impacted by economic assumptions and other non-recurring costs.
- NobleOak exhibited disciplined insurance risk management, leading to improved insurance margins.
- A significant growth in market share was observed, now holding 4.1% of the individual life risk market.
- The company continues to transition to a Life Company structure, aiming for long-term capital efficiency and governance improvements.
- NobleOak's Embedded Value (EV) increased by 90% since IPO, reflecting strong growth potential.
- The company is leveraging AI and automation to enhance customer experience and operational efficiency.
- NobleOak was named Life Insurance Company of the Year 2025 by the Australian and New Zealand Institute of Insurance and Finance.
- The company plans a strategic focus on expanding digital platforms and entering new product adjacencies to drive growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$133 |
NobleOak FY25 Results Presentation
|
29 Aug 2025 8:23AM |
$1.355 |
$1.435 |
risen by
5.90%
|
|
NOL - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong in-force premium growth and margin expansion.
- Statutory profit of $7.1 million with 52% NPAT growth.
- Transitioning to a Life Company structure for better capital efficiency.
- Continued market share growth driven by digital investment.
- Robust capital position with a capital adequacy multiple of 186%.
- Strategic acquisition of RevTech aids in margin expansion.
- Investment in AI and digital platforms for enhanced market presence.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NAOS Ex-50 Opportunities Company Limited (NAC) ORDINARY FULLY PAID |
Financials |
$27 |
Change of Director's Interest Notice - S Evans
|
29 Aug 2025 8:22AM |
$0.565 |
$0.580 |
risen by
2.65%
|
|
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$133 |
NobleOak FY25 Results Release
|
29 Aug 2025 8:22AM |
$1.355 |
$1.435 |
risen by
5.90%
|
|
NOL - Price-sensitive ASX Announcement
Full Release
Key Points
- In-force premiums grew 20% to $464.2 million as of 30 June 2025.
- Underlying NPAT increased by 22% to $18.3 million.
- Statutory NPAT reduced by 23% to $7.1 million due to provisions and economic changes.
- Embedded Value published at $197.6 million, reflecting strong growth trajectory.
- Transition to a Life Company structure to enhance capital efficiency.
- New partnerships and products to drive future growth.
- FY26 targets include over 15% growth in in-force premiums and over 10% growth in NPAT.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
